Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the immunotherapy developer.

France-based T-cell therapy developer Egle Therapeutics has closed a €40m ($46.5m) series A round that included Takeda Ventures, the strategic investment arm of pharmaceutical firm Takeda.

Public investment bank BPIfrance’s InnoBio 2 fund co-led the round with life sciences investment firm LSP, and it also featured venture capital fund Fund+ and investment firm Bioqube Ventures.

Egle is working on immunotherapies designed to fight cancer and autoimmune diseases by targeting immune suppressor regulatory T-cells (Tregs). It was spun out of research…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn